Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington. Show more

Location: 18702 North Creek Parkway, Bothell, WA, 98011, United States | Website: https://immunome.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

791.2M

52 Wk Range

$5.15 - $16.55

Previous Close

$9.09

Open

$9.08

Volume

1,162,404

Day Range

$8.92 - $9.46

Enterprise Value

527.3M

Cash

268M

Avg Qtr Burn

-44.67M

Insider Ownership

11.50%

Institutional Own.

87.04%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.